REFERENCES
1. Sampath V, Abrams EM, Adlou B, et al. Food allergy across the globe.J Allergy Clin Immunol. 2021;148(6):1347-1364.
2. Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States.Pediatrics. 2018;142(6).
3. Gupta RS, Warren CM, Smith BM, et al. Prevalence and Severity of Food Allergies Among US Adults. JAMA Netw Open. 2019;2(1):e185630.
4. Grabenhenrich L, Trendelenburg V, Bellach J, et al. Frequency of food allergy in school-aged children in eight European countries-The EuroPrevall-iFAAM birth cohort. Allergy. 2020;75(9):2294-2308.
5. DunnGalvin A, Blumchen K, Timmermans F, et al. APPEAL-1: A multiple-country European survey assessing the psychosocial impact of peanut allergy. Allergy. 2020;75(11):2899-2908.
6. Jakobsen LS, Pilegaard K, Pires SM, Bogh KL. The disease burden of peanut allergy in Denmark measured by disability-adjusted life years (DALYs). Allergy. 2021;76(5):1583-1585.
7. Lieberman JA, Gupta RS, Knibb RC, et al. The global burden of illness of peanut allergy: A comprehensive literature review. Allergy.2021;76(5):1367-1384.
8. Fernandez-Rivas M, Vereda A, Vickery BP, et al. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.Allergy. 2022;77(3):991-1003.
9. Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis.Allergy. 2017;72(8):1133-1147.
10. Phelps A, Bruton K, Grydziuszko E, Koenig JFE, Jordana M. The Road Toward Transformative Treatments for Food Allergy. Front Allergy.2022;3:826623.
11. Al Hawi Y, Nagao M, Furuya K, et al. Agreement Between Predictive, Allergen-Specific IgE Values Assessed by ImmunoCAP and IMMULITE 2000 3gAllergy Assay Systems for Milk and Wheat Allergies. Allergy Asthma Immunol Res. 2021;13(1):141-153.
12. Goyard S, Balbino B, Chinthrajah RS, et al. A highly sensitive bioluminescent method for measuring allergen-specific IgE in microliter samples. Allergy. 2020;75(11):2952-2956.
13. Suarez-Farinas M, Suprun M, Kearney P, et al. Accurate and reproducible diagnosis of peanut allergy using epitope mapping.Allergy. 2021;76(12):3789-3797.
14. Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice. Allergy. 2021;76(8):2420-2432.
15. Duan L, Celik A, Hoang JA, et al. Basophil activation test shows high accuracy in the diagnosis of peanut and tree nut allergy: The Markers of Nut Allergy Study. Allergy. 2021;76(6):1800-1812.
16. Decuyper, II, Pascal M, Van Gasse AL, et al. Performance of basophil activation test and specific IgG4 as diagnostic tools in nonspecific lipid transfer protein allergy: Antwerp-Barcelona comparison.Allergy. 2020;75(3):616-624.
17. Santos AF, Bergmann M, Brough HA, et al. Basophil Activation Test Reduces Oral Food Challenges to Nuts and Sesame. J Allergy Clin Immunol Pract. 2021;9(5):2016-2027 e2016.
18. Alpan O, Layhadi JA, Ulrik Sonder S, Li H, Shamji MH. Basophil activation test: A diagnostic, predictive and monitoring assay for allergen immunotherapy. Allergy. 2021;76(5):1321-1324.
19. Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.Lancet. 2019;394(10207):1437-1449.
20. Tsai M, Mukai K, Chinthrajah RS, Nadeau KC, Galli SJ. Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE. J Allergy Clin Immunol.2020;145(3):885-896 e886.
21. Behrends J, Schwager C, Hein M, Scholzen T, Kull S, Jappe U. Innovative robust basophil activation test using a novel gating strategy reliably diagnosing allergy with full automation. Allergy.2021;76(12):3776-3788.
22. Santos AF, Kulis MD, Sampson HA. Bringing the Next Generation of Food Allergy Diagnostics Into the Clinic. J Allergy Clin Immunol Pract. 2022;10(1):1-9.
23. Monino-Romero S, Lexmond WS, Singer J, et al. Soluble FcvarepsilonRI: A biomarker for IgE-mediated diseases. Allergy.2019;74(7):1381-1384.
24. Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.Allergy. 2020;75(12):3039-3068.
25. Ogulur I, Pat Y, Ardicli O, et al. Advances and highlights in biomarkers of allergic diseases. Allergy. 2021;76(12):3659-3686.
26. Ehlers AM, den Hartog Jager CF, Knulst AC, Otten HG. Distinction between peanut allergy and tolerance by characterization of B cell receptor repertoires. Allergy. 2021;76(9):2753-2764.
27. Arasi S, Nurmatov U, Dunn-Galvin A, et al. Consensus on DEfinition of Food Allergy SEverity (DEFASE) an integrated mixed methods systematic review. World Allergy Organ J. 2021;14(3):100503.
28. Dribin TE, Schnadower D, Spergel JM, et al. Severity grading system for acute allergic reactions: A multidisciplinary Delphi study. J Allergy Clin Immunol. 2021;148(1):173-181.
29. Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233-243.
30. Chinthrajah RS, Jones SM, Kim EH, et al. Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy. J Allergy Clin Immunol. 2022.
31. Fernandez-Rivas M, Gomez Garcia I, Gonzalo-Fernandez A, et al. Development and validation of the Food Allergy Severity Score.Allergy. 2021.
32. Purington N, Chinthrajah RS, Long A, et al. Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food Challenges. Front Immunol. 2018;9:2057.
33. Chinthrajah RS, Purington N, Andorf S, et al. Development of a tool predicting severity of allergic reaction during peanut challenge.Ann Allergy Asthma Immunol. 2018;121(1):69-76 e62.
34. Patel N, Adelman DC, Anagnostou K, et al. Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis.J Allergy Clin Immunol. 2021;147(6):2249-2262 e2247.
35. Turner PJ, Patel N, Ballmer-Weber BK, et al. Peanut Can Be Used as a Reference Allergen for Hazard Characterization in Food Allergen Risk Management: A Rapid Evidence Assessment and Meta-Analysis. J Allergy Clin Immunol Pract. 2022;10(1):59-70.
36. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med.2015;372(9):803-813.
37. Fleischer DM, Sicherer S, Greenhawt M, et al. Consensus Communication on Early Peanut Introduction and Prevention of Peanut Allergy in High-Risk Infants. Pediatr Dermatol.2016;33(1):103-106.
38. Azad MB, Dharma C, Simons E, et al. Reduced peanut sensitization with maternal peanut consumption and early peanut introduction while breastfeeding. J Dev Orig Health Dis. 2021;12(5):811-818.
39. Rosario Filho N. [Early introduction of food to prevent food allergy. The LEAP study (Learning Early about Peanut)]. Rev Paul Pediatr. 2015;33(4):493-494.
40. Du Toit G, Sampson HA, Plaut M, Burks AW, Akdis CA, Lack G. Food allergy: Update on prevention and tolerance. J Allergy Clin Immunol. 2018;141(1):30-40.
41. du Toit G, Sayre PH, Roberts G, et al. Allergen specificity of early peanut consumption and effect on development of allergic disease in the Learning Early About Peanut Allergy study cohort. J Allergy Clin Immunol. 2018;141(4):1343-1353.
42. Yakaboski E, Robinson LB, Arroyo A, et al. Early Introduction of Food Allergens and Risk of Developing Food Allergy. Nutrients.2021;13(7).
43. Marques-Mejias MA, Fisher H, Lack G, Du Toit G. Translating research into practice: What’s new in the 2021 EAACI food allergy prevention guidelines? Clin Exp Allergy. 2022;52(4):476-480.
44. Sakihara T, Otsuji K, Arakaki Y, Hamada K, Sugiura S, Ito K. Randomized trial of early infant formula introduction to prevent cow’s milk allergy. J Allergy Clin Immunol. 2021;147(1):224-232 e228.
45. Holl JL, Bilaver LA, Finn DJ, Savio K. A randomized trial of the acceptability of a daily multi-allergen food supplement for infants.Pediatr Allergy Immunol. 2020;31(4):418-420.
46. Krawiec M, Fisher HR, Du Toit G, Bahnson HT, Lack G. Overview of oral tolerance induction for prevention of food allergy-Where are we now? Allergy. 2021;76(9):2684-2698.
47. Amazouz H, de Lauzon-Guillain B, Bourgoin-Heck M, et al. Infant feeding clusters are associated with respiratory health and allergy at school age in the PARIS birth cohort. Allergy.2021;76(4):1223-1234.
48. Adjibade M, Davisse-Paturet C, Bernard JY, et al. Enrichment of infant formula with long-chain polyunsaturated fatty acids and risk of infection and allergy in the nationwide ELFE birth cohort.Allergy. 2021.
49. Brough HA, Nadeau KC, Sindher SB, et al. Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented? Allergy. 2020;75(9):2185-2205.
50. Warnberg Gerdin S, Lie A, Asarnoj A, et al. Impaired skin barrier and allergic sensitization in early infancy. Allergy. 2021.
51. Mortz CG, du Toit G, Beyer K, et al. When and how to evaluate for immediate type food allergy in children with atopic dermatitis.Allergy. 2021;76(12):3845-3848.
52. Sindher S, Alkotob SS, Shojinaga MN, et al. Pilot study measuring transepidermal water loss (TEWL) in children suggests trilipid cream is more effective than a paraffin-based emollient. Allergy.2020;75(10):2662-2664.
53. Sindher S, Alkotob SS, Shojinaga MN, et al. Increases in plasma IgG4/IgE with trilipid vs paraffin/petrolatum-based emollients for dry skin/eczema. Pediatr Allergy Immunol. 2020;31(6):699-703.
54. Zhong Y, Samuel M, van Bever H, Tham EH. Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis.Allergy. 2021.
55. Brough HA, Lanser BJ, Sindher SB, et al. Early intervention and prevention of allergic diseases. Allergy. 2022;77(2):416-441.
56. Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial.Lancet. 2020;395(10228):962-972.
57. Perkin MR, Logan K, Marrs T, et al. Association of frequent moisturizer use in early infancy with the development of food allergy.J Allergy Clin Immunol. 2021;147(3):967-976 e961.
58. Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol.2018;178(1):e19-e21.
59. Sampath V, Sindher SB, Alvarez Pinzon AM, Nadeau KC. Can food allergy be cured? What are the future prospects? Allergy.2020;75(6):1316-1326.
60. de Silva D, Rodriguez Del Rio P, de Jong NW, et al. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. Allergy. 2022.
61. Eiwegger T, Hung L, San Diego KE, O’Mahony L, Upton J. Recent developments and highlights in food allergy. Allergy.2019;74(12):2355-2367.
62. Yu S, Smith A, Hass S, et al. The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy. Adv Ther. 2021;38(8):4321-4332.
63. Investigators PGoC, Vickery BP, Vereda A, et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med.2018;379(21):1991-2001.
64. Vickery BP, Vereda A, Nilsson C, et al. Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study. J Allergy Clin Immunol Pract.2021;9(5):1879-1889 e1814.
65. Kim EH, Burks AW. Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy. Allergy. 2020;75(6):1337-1346.
66. Bajzik V, DeBerg HA, Garabatos N, et al. Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses. Allergy. 2022.
67. Elizur A, Appel MY, Nachshon L, et al. Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study).Allergy. 2022.
68. Epstein-Rigbi N, Goldberg MR, Levy MB, Nachshon L, Elizur A. Quality of life of children aged 8-12 years undergoing food allergy oral immunotherapy: Child and parent perspective. Allergy.2020;75(10):2623-2632.
69. Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK, team Ps. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. Allergy. 2018;73(3):560-568.
70. Rigbi NE, Goldberg MR, Levy MB, Nachshon L, Golobov K, Elizur A. Changes in patient quality of life during oral immunotherapy for food allergy. Allergy. 2017;72(12):1883-1890.
71. Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.Lancet. 2022;399(10322):359-371.
72. Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.JAMA. 2019;321(10):946-955.
73. Scurlock AM, Burks AW, Sicherer SH, et al. Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research. J Allergy Clin Immunol.2021;147(3):992-1003 e1005.
74. Fleischer DM, Shreffler WG, Campbell DE, et al. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results.J Allergy Clin Immunol. 2020;146(4):863-874.
75. Fleischer DM, Chinthrajah S, Scurlock AM, et al. An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial. Allergy Asthma Proc.2020;41(5):326-335.
76. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275-1282 e1271-1276.
77. Tomsitz D, Biedermann T, Brockow K. Sublingual immunotherapy reduces reaction threshold in three patients with wheat-dependent exercise-induced anaphylaxis. Allergy. 2021;76(12):3804-3806.
78. Kim EH, Yang L, Ye P, et al. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2019;144(5):1320-1326 e1321.
79. Savage JH, Lee-Sarwar KA, Sordillo J, et al. A prospective microbiome-wide association study of food sensitization and food allergy in early childhood. Allergy. 2018;73(1):145-152.
80. Fazlollahi M, Chun Y, Grishin A, et al. Early-life gut microbiome and egg allergy. Allergy. 2018;73(7):1515-1524.
81. He Z, Vadali VG, Szabady RL, et al. Increased diversity of gut microbiota during active oral immunotherapy in peanut-allergic adults.Allergy. 2021;76(3):927-930.
82. Loke P, Orsini F, Lozinsky AC, et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. Lancet Child Adolesc Health. 2022;6(3):171-184.
83. Jing W, Liu Q, Wang W. Bifidobacterium bifidum TMC3115 ameliorates milk protein allergy in by affecting gut microbiota: A randomized double-blind control trial. J Food Biochem. 2020;44(11):e13489.
84. Sindher SB, Kumar D, Cao S, et al. Phase 2, randomized multi oral immunotherapy with omalizumab ’real life’ study. Allergy. 2022.
85. Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: Evidence from a cohort of 181 patients. J Allergy Clin Immunol. 2021;147(1):233-243.
86. Begin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7.
87. Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol.2018;3(2):85-94.
88. Manohar M, Dunham D, Gupta S, et al. Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab.Allergy. 2021;76(9):2809-2826.
89. Andorf S, Purington N, Kumar D, et al. A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals. EClinicalMedicine. 2019;7:27-38.
90. Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol.2016;137(4):1103-1110 e1111.
91. Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol.2011;127(5):1309-1310 e1301.
92. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol.2011;127(6):1622-1624.
93. Bedoret D, Singh AK, Shaw V, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow’s milk allergy enabled with omalizumab. Mucosal Immunol.2012;5(3):267-276.
94. Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.
95. Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 2016;138(4):1051-1059.
96. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371-1385.
97. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.Gastroenterology. 2020;158(1):111-122 e110.
98. Warren CM, Jiang J, Gupta RS. Epidemiology and Burden of Food Allergy. Curr Allergy Asthma Rep. 2020;20(2):6.
99. O’Loughlin R, Hiscock H. Presentations to emergency departments by children and young people with food allergy are increasing. Med J Aust. 2020;213(1):27-29.